Akari CEO says ADC sector shifts to “2.0” as demand grows for novel payloads

PUBT·06/04/2026 13:30:22

Listen to the news

Akari released a CEO Corner interview with CEO Abizer Gaslightwala on themes from ASCO 2026 and the shifting antibody-drug conjugate landscape.
Gaslightwala flagged rising focus on hard-to-treat, genetically defined cancers, citing KRAS-driven tumors as a key unmet-need area.
He argued the sector is moving to “ADC 2.0,” with demand for new payload classes as sequential ADCs using the same payload show limited efficacy.
He highlighted Akari’s PH1 spliceosome-modulating payload platform as a potential option to address resistance seen with Top1 or MMAE payloads.
Management reiterated plans to start a Phase 1 first-in-human trial of lead candidate AKTX-101 by mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606040930PRIMZONEFULLFEED9731934) on June 04, 2026, and is solely responsible for the information contained therein.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number :+852 3852 8500

Monday 7:00 AM - Saturday 9:00 AM (HKT)

Service Email :service@webull.hk

Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)

Business Cooperation :marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English